Respiratory
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Chiesi Returns To Respiratory Roots With Affibody Pact
A busy start to the year sees the Italian firm adding to its respiratory portfolio by gaining access to the Swedish biotech’s investigational inhaled treatments.
Theravance Dumps JAK Inhibitor Program, Focuses On Neurogenic Orthostatic Hypotension
Ampreloxetine failed in a Phase III trial in 2021, but the company will start a registrational trial by the end of Q1 for the drug in the multiple system atrophy population, where it has shown efficacy.
Sobi Maintains Grip On RSV Market – For Now
Vaccines and new antibody drugs are set to transform the respiratory syncytial virus space but for now, the Swedish rare disease specialist’s 25-year old offering Synagis is enjoying increased demand.
Aridis' Monoclonal Antibody Rouses Analyst Optimism Despite Pneumonia Phase III Miss
The US biotech’s lead candidate missed the mark in a Phase III hospital-related pneumonia trial due to low recruitment affected by macroeconomic headwinds but analysts retain high hopes for another upcoming study.
Phase III Results Show Moderna Could Challenge In Blockbuster RSV Vaccine Market
Moderna has moved fast to catch up with GSK and Pfizer, but will still be up to a year behind in reaching the market in the burgeoning RSV market.
Airsupra Could Help Revive AstraZeneca's Respiratory Fortunes
The US Food and Drug Administration has approved AstraZeneca and Avillion’s respiratory drug Airsupra, making it the only rescue medication cleared for as-needed use to reduce risk of asthma exacerbations.
Chiesi Expands Its Rare Disease Reach With $1.48bn Amryt Buyout
The privately owned company currently earns most of its revenues in respiratory medicine in Europe, but has set its sights on expanding in rare diseases and the US market.
Verona Emerges Victorious From Second COPD Trial
After once again showing significant improvements in lung function and a 36% reduction in rate of exacerbations over 24 weeks, Verona is confident that its dual PDE3/4 inhibitor will change the treatment paradigm for COPD.
Pulmocide Grows Cash Pile For Promising Antifungal
The UK firm has announced an extension of its series C financing which means it has raised just shy of $150m in the last 18 months to fund clinical development, manufacturing scale-up and preparations for the potential commercialization of opelconazole.
C4XD Inks Third Major Deal, This Time With AZ For Oral COPD Drug
The UK firm has out-licensed its NRF2 activator programme to AstraZeneca in its third major deal of the year as it works to stabilize cash flow through a broad-ranging approach to partnerships.
GSK To Take ‘Smart Risks’ Across Portfolio – But Will Be ‘Pragmatic’ About Oncology Expansion
GSK’s new R&D leader, Tony Wood, has promised a more hard-nosed attitude to picking winners – including a ‘pragmatic’ approach to the hyper-competitive field of oncology.
Flush With CF Success, Vertex Prepares Next-Gen Pipeline For Busy 2023
Vertex’s dominance in cystic fibrosis looks secure for years to come, and 2023 and 2024 could see it bring more ground-breaking innovation to market.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.